Other World Computing Introduces Intel Thunderbolt Share for the Thunderbolt Go Dock
Exciting New Application from Intel Enables Fast PC-to-PC Connectivity TAIPEI, Taiwan--(BUSINESS WIRE)--#Intel--Other World Computing –…
2 years ago
Stronger Than Ever: Adani Portfolio Delivers Record Performance
45% EBITDA growth in FY24, EBITDA reaches USD 10 Bn Adani Portfolio EBITDA increased to…
2 years ago
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
Integration enhances the Denodo Platform, providing enterprise customers with faster, more secure, and fully scalable…
2 years ago
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
At the office opening today, Ãngel Viña, CEO of Denodo will be joined by Dr.…
2 years ago
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca’s ENHERTU is the first HER2 directed medicine and…
2 years ago
CLPð‘’ Teams Up with CityUHK to Install Solar Power System Across the Campus
HONG KONG SAR - Media OutReach Newswire - 2 June 2024 - CLPe and City…
2 years ago
OPPO Scores Unforgettable Experiences with Global Brand Ambassador KakaÌ at the UEFA Champions League Final 2024
LONDON, UNITED KINGDOM - Media OutReach Newswire – 1 June 2024 - The UEFA Champions…
2 years ago
“Experience the Luxury of Japanese Tradition and Cuisine” Reservations for the New Inbound Experience Tour in Osaka’s Tondabayashi Begin on June 1, 2024!
OSAKA, Japan--(BUSINESS WIRE)--The city of Tondabayashi in Osaka is excited to announce a new inbound…
2 years ago
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
− Four-year Analysis Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing…
2 years ago
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
– Differentiated Mechanism of Action of a Chimeric Degrader as Compared to Fulvestrant and Novel…
2 years ago